Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine
about
Legal highs: staying on top of the flood of novel psychoactive substancesCharacterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokineticsCharacterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolamDetection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokineticsDetection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism.ELISA Detection of Phenazepam, Etizolam, Pyrazolam, Flubromazepam, Diclazepam and Delorazepam in Blood Using Immunalysis® Benzodiazepine Kit.Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes.Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS.Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine.The emergence of new psychoactive substance (NPS) benzodiazepines: A review.Designer benzodiazepines: A new challenge.Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry.Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites
P2860
Q26799231-954A3CA9-6347-49F6-99EE-D02C85F407ACQ28235472-9EBBA58A-D598-4C35-A3E4-6FC51D3BCBC8Q28277912-2D5C8B5A-4679-4209-BD7B-8AB84E6A0E67Q28302395-E06D8609-268C-4C37-BE6B-DCCDFC96EF28Q31133258-03A68430-D6AE-49BE-8110-B8FDFFD8745AQ34499984-3ADCA358-98FE-49BD-AD82-EEDFBB575D06Q34521916-EACF7301-6A0C-4D7D-ADDE-518A671AA18AQ34532586-221367D4-1283-4A0B-B607-E32361EBC6B0Q38260819-152478EF-27BC-47F7-9551-1DB9B1BB040AQ38853831-7208E6F4-DDAC-4598-8B47-4AC3C8BB9161Q39282924-9C543B47-3A6D-492F-87AC-8029340ACE7AQ42425129-5B7D3015-1347-4006-ACBB-5932BDB43714Q48176056-EA50BFF2-130B-4D56-BD56-476470E4B46CQ56532318-0F48F1C3-DACC-4395-A9AE-18B8F755490C
P2860
Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2013
@uk
name
Characterization of the design ...... ility in human serum and urine
@en
Characterization of the design ...... ility in human serum and urine
@nl
type
label
Characterization of the design ...... ility in human serum and urine
@en
Characterization of the design ...... ility in human serum and urine
@nl
prefLabel
Characterization of the design ...... ility in human serum and urine
@en
Characterization of the design ...... ility in human serum and urine
@nl
P2093
P2860
P1433
P1476
Characterization of the design ...... ility in human serum and urine
@en
P2093
Bjoern Moosmann
Laura M. Huppertz
Lisa Redlingshöfer
Melanie Hutter
Sascha Ferlaino
Volker Auwärter
P2860
P2888
P304
P356
10.1007/S11419-013-0187-4
P577
2013-04-27T00:00:00Z